Epeius Biotechnologies Corporation Receives $400,000 Grant to Support Gene Therapy Trials for Pancreatic Cancer
Posted on: Monday, 19 June 2006, 09:00 CDT
SAN MARINO, Calif., June 19 /PRNewswire/ -- Epeius Biotechnologies Corporation announced today that the Company has been awarded a $400,000 grant by the Lazarex Cancer Foundation to expand and support ongoing cancer gene therapy clinical trials for advanced and metastatic pancreatic cancer. Rexin-GTM is the world's first targeted injectable gene therapy vector to be approved for use in clinical trials in the USA and abroad. When injected intravenously, Rexin-GTM seeks out and destroys metastatic cancer, without the systemic toxicity generally associated with chemotherapy.
*(LOGO: Send2Press.com/mediadesk/logo-epeius_72dpi.jpg)
Rexin-GTM recently gained Orphan Drug status as an effective treatment for pancreatic cancer in the United States, and is currently available in clinical trials in Rochester MN.
In a statement to the press, Ms. Dana Dornsife, President of the Lazarex Cancer Foundation said: "We are pleased to provide Epeius Biotechnologies Corporation the funds needed to expedite the development of such promising genetic medicines, which -- by improving both the survival and the quality of life -- provide cancer patients with more quality time."
More information: http://www.epeiusbiotech.com/
This release was issued on behalf of the above organization by Send2Press(R), a unit of Neotrope(R). http://www.send2press.com/
Epeius Biotechnologies Corporation
CONTACT: Clinical Trials, Dr. Erlinda M. Gordon, Medical Director, orMedia, Dr. Frederick L. Hall, President and CEO, both of EpeiusBiotechnologies Corporation, +1-626-441-6695, or fax, +1-626-441-6692,info@epeiusbiotech.com
Web site: http://www.epeiusbiotech.com/
Source: PRNewswire
Related Articles
- Biothera Completes Enrollment of First Arm of Colorectal Cancer Trial
- Celsion Provides Update on Its Global Pivotal Phase III Primary Liver Cancer Trial
- Bostwick Wins Approval to Initiate Phase I/II Prostate Cancer Trial
- CTCA Initiates Phase I/II Ovarian Cancer Trial
- CELSION Secures Special Protocol Assessment of Its Pivotal Phase III Liver Cancer Trial From FDA
- Results of RTA 402 Phase I Cancer Trial Presented at AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
- ZIOPHARM Announces Interim Results in ZIO-101 Phase I Solid Tumor Cancer Trial; Clinical Activity in Several Cancers
- Pro-Pharmaceuticals Retains Dr. James T. Gourzis to Provide Clinical Management & Strategic Development of Its Europe-Based Phase III Colorectal Cancer Trial
- Antigenics Updates Business Strategy and Outlines Timeline for the Analysis of Its Phase 3 Kidney Cancer Trial
- Peregrine Pharmaceuticals Opens Patient Enrollment for Its Tarvacin(TM) Phase I Solid Cancer Therapy Clinical Trial
 |
 |
User Comments (0)
RSS Feeds